Researchers at the University of Alabama at Birmingham will study individuals with genetic mutations associated with Parkinson’s disease as one of 32 clinical sites of the Parkinson’s Progression Markers Initiative (PPMI), a large-scale biomarker study sponsored by The Michael J. Fox Foundation for Parkinson’s Research.
PPMI will enroll participants with a known mutation of the LRRK or SNCA [alpha-synuclein] gene. Previous research has shown these mutations are associated with Parkinson’s disease and account for a greater number of PD cases among certain ethnic populations and families, notably the LRRK2 mutation in those of Ashkenazi (Eastern European) Jewish, Basque and North African Berber descent. The insight investigators glean from these research volunteers will fortify current efforts to develop a disease-modifying therapy, something that currently eludes the field.
“Studying individuals with genetic mutations associated with Parkinson’s can accelerate our research toward a PD biomarker and more effective treatments,” said David Standaert, M.D., Ph.D., chair of the Department of Neurology and primary investigator at UAB. “Although known genetic mutations account for only five to 10 percent of all Parkinson’s cases, this population can provide invaluable information about the intricacies of the disease for all patients.”
PPMI is studying clinical and imaging data and biological samples of people with a genetic mutation to identify biomarkers and speed clinical trials. PPMI will enroll 250 people with the LRRK2 mutation and Parkinson’s, and 250 people with the mutation but without Parkinson’s. Since the SNCA mutation is more rare, the study is recruiting 50 people with Parkinson’s and the mutation, and 50 people with the SNCA mutation but without PD. These participants will be followed for five years.
Interested individuals can visit www.michaeljfox.org/ppmi/genetics, call 877-836-8108 or e-mail firstname.lastname@example.org. PPMI is particularly interested in testing individuals of Ashkenazi (Eastern European) Jewish descent or their relatives with Parkinson’s. The LRRK2 mutation also accounts for more PD cases in people of North African Arab Berber or Basque descent. Study sites will recruit people with the rarer SNCA mutation through familial connections.
Biomarkers — such as cholesterol level for heart disease — are substances, processes or characteristics of the body that communicate disease risk, onset and/or progression. They aid in diagnosis and disease management and help researchers stratify for clinical trials and test new drugs more quickly by measuring biological changes rather than waiting for clinical improvement. There are no validated biomarkers for Parkinson’s disease, a reality researchers are hoping to change with PPMI.
Launched in 2010, PPMI is a longitudinal clinical study that collects standardized clinical, imaging and biologic data. Now taking place at 32 clinical sites around the world, the study completed initial enrollment of 423 recently diagnosed Parkinson’s patients and 196 controls in April 2013. That month, PPMI began recruiting individuals with the known Parkinson’s risk factors of smell loss and REM sleep behavior disorder.
“In the fourth year of PPMI, it is evident that a large-scale biomarker study is not only possible in Parkinson’s disease, but is already yielding scientific insights that could help transform the field of Parkinson’s research,” said Todd Sherer, Ph.D., CEO of The Michael J. Fox Foundation. “The exceptional investigators at sites around the world, such as at UAB, have created the infrastructure that allows us to make such strides, by working together.”
Study to test ways to improve cognitive functioning of older adults with HIVUAB School of Nursing Professor David Vance, Ph.D., received a five-year, $2.86 million R01 grant to test ways of improving cognitive function in older adults with HIV.posted 3 days ago 339 viewsUAB Cancer Center creates coalition to increase HPV vaccination ratesThe UAB Comprehensive Cancer Center has developed a statewide coalition to increase uptake of HPV vaccinations in Alabama.posted 4 days ago 273 viewsDebunking digital eyestrain and blue light mythsAdam Gordon, O.D., discusses blue light, including the lack of clinical evidence in advertisements overstating dangers, as well as the effects of blue light on sleep and eye discomfort.posted 4 days ago 798 viewsA call to Kenya: Ben Roberts seeks to restore vision near and farUAB School of Medicine alumnus uses his talents and his faith to give the gift of sight to those in Kenya and Alabama.posted 10 days ago 1897 viewsTrussville baby with rare hypoplastic left heart condition celebrates first birthdayUAB News introduced Baby JJ and the Burford family to the public in 2015. After two difficult surgeries in his first year of life, Jeremiah reaches a milestone in his road to recovery.posted 14 days ago 941 viewsUAB Medical Genomics Laboratory refines its genetic testing technologyCustomized deep-coverage, next-generation sequencing will replace the current state-of-the-art approach.posted 15 days ago 1055 viewsPalliative care makes every moment countPalliative care helps patients get the most out of life, whether they’re newly diagnosed, a survivor, or nearing the end of their journey. UAB’s palliative care pioneers provide a fresh look at the fast-growing specialty and its emphasis on listening, choices, patient goals, and quality of life.posted 14 days ago 704 viewsAlabama Organ Center celebrates National Donate Life Month, National Blue and Green DayAlabama landmarks will change their colors to bring awareness to the need for Alabama’s residents to register to be organ donors.
UAB awarded $19.5 million grant for new xenotransplantation programGift from United Therapeutics will establish Xenotransplantation Institute and bring additional resources to support the endeavor with a goal of genetically modified kidney transplants taking place by 2021.posted 21 days ago 4255 viewsFertility Care Network provides infertility resources to families throughout stateInfertility choices for women are expanded with UAB Fertility Care Network.posted 24 days ago 1470 viewsNew study explores patient navigator effect for those with diabetesRole of mentors for patients with diabetes is the focus of a $30,000 grant.posted 25 days ago 1383 viewsChicago teen who arrived at UAB Hospital on Christmas Eve set to go home after remarkable recoveryMichelle Harris came to UAB on maximal life support, unsure if she would live after a rare multisystem autoimmune disease attacked her lungs. Now, she will go home with her eyes on upcoming prom and graduation.posted a while back 6001 viewsUAB Hospital recognized as a leader in health care equalityUAB becomes one of only six hospitals in Alabama to be recognized as a leader in health care equality.posted a while back 2004 viewsNew study explores carb-loading’s effect on heartA new multi-institutional study looks at the negative effects of a high-carbohydrate diet on the heart.posted a while back 1973 viewsUnderstanding and improving treatment adherence: A research opportunity and patient needPart of the challenge is to do a better job of helping patients make their own, well-informed choices.posted a while back 1403 viewsSpring daylight saving time may cause an increased risk of heart attacksSpringing forward with daylight saving time may increase your risk of having a heart attack if you have a history of heart disease.posted a while back 3567 viewsOparil one of three doctors to receive national clinical excellence awardUAB’s Suzanne Oparil, M.D., has been selected as one of only three doctors from the United States to receive the Clinical Excellence Award at the National Physician of the Year Awards in New York City.posted a while back 1701 viewsColor Run to benefit UAB Comprehensive Cancer CenterOak Mountain High School will host the third annual Color Run 5K at Oak Mountain State Park on March 12 to raise money for cancer research at UAB.
- Event Date April 15
UAB clinical trial study finds ovarian cancer survival rates did not rise with increased paclitaxelResearch study conducted at UAB shows that weekly dosage of paclitaxel versus three-week treatment does not prolong progression-free survival in patients with ovarian cancer.posted a while back 2398 viewsUAB holds full-scale disaster drill with local, state and national agenciesUAB leads local hospitals, first responders and government agencies in full-scale tornado disaster exercise.posted a while back 1431 views
- Event Date March 12